D'Youville University Syracuse, New York, United States
Abstract Body : This research aims to compare the effectiveness of botulinum toxin, specifically type A (BTX-A), with placebo interventions in alleviating pain among individuals diagnosed with sleep bruxism through a meta-analysis. The objective was to gain a clearer insight into the current available management options for pain relief in individuals with sleep bruxism. The hypothesis posits that BTX-A is more effective in reducing pain compared to other placebo interventions for participants with sleep bruxism. The methods employed in this research are derived from previously published research papers. Inclusion criteria for these papers encompass information on BTX-A and placebo interventions for sleep bruxism. Participants selected for the present research must have possessed a clinical diagnosis of sleep bruxism and experience pain. This research sought to clearly identify which type of intervention has a greater effect on reducing pain as a consequence of sleep bruxism. Baseline assessments were compared to follow-up assessments of pain at 2 weeks, 1 month, 3 months, and 6 months post-injection. Significant data were observed at 2 weeks , 1 month, and 3 months. Assessments highlighted a substantial decrease in pain associated with sleep bruxism through the application of BTX-A. The findings indicated pain began to recur after a period of 6 months. Therefore, the administration of BTX-A injections demonstrates efficacy in reducing pain for a duration of up to six months in individuals with sleep bruxism.
